585 related articles for article (PubMed ID: 17944738)
1. Clinical trial: randomized-controlled clinical study comparing the efficacy and safety of a low-volume vs. a high-volume mesalazine foam in active distal ulcerative colitis.
Eliakim R; Tulassay Z; Kupcinskas L; Adamonis K; Pokrotnieks J; Bar-Meir S; Lavy A; Mueller R; Greinwald R; Chermesh I; Gross V;
Aliment Pharmacol Ther; 2007 Nov; 26(9):1237-49. PubMed ID: 17944738
[TBL] [Abstract][Full Text] [Related]
2. Mesalazine foam (Salofalk foam) in the treatment of active distal ulcerative colitis. A comparative trial vs Salofalk enema. The SAF-3 study group.
Ardizzone S; Doldo P; Ranzi T; Sturniolo GC; Giglio LA; Annese V; D'Arienzo A; Gaia E; Gullini S; Riegler G; Valentini M; Massa P; Del Piano M; Rossini F; Guidetti CS; Pera A; Greinwald R; Bianchi Porro G
Ital J Gastroenterol Hepatol; 1999 Nov; 31(8):677-84. PubMed ID: 10730559
[TBL] [Abstract][Full Text] [Related]
3. Mesalamine foam enema versus mesalamine liquid enema in active left-sided ulcerative colitis.
Cortot A; Maetz D; Degoutte E; Delette O; Meunier P; Tan G; Cazals JB; Dewit O; Hebuterne X; Beorchia S; Grunberg B; Leprince E; D'Haens G; Forestier S; Idier I; Lémann M
Am J Gastroenterol; 2008 Dec; 103(12):3106-14. PubMed ID: 19086960
[TBL] [Abstract][Full Text] [Related]
4. [Budesonide foam as a new therapeutic principle in distal ulcerative colitis in comparison with mesalazine enema. An open, controlled, randomized and prospective multicenter pilot study].
Rufle W; Frühmorgen P; Huber W; Kimmig JM
Z Gastroenterol; 2000 Apr; 38(4):287-93. PubMed ID: 10820860
[TBL] [Abstract][Full Text] [Related]
5. Mesalazine (5-aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis--results from a randomized-controlled trial.
Raedler A; Behrens C; Bias P
Aliment Pharmacol Ther; 2004 Dec; 20(11-12):1353-63. PubMed ID: 15606398
[TBL] [Abstract][Full Text] [Related]
6. Beclomethasone dipropionate versus mesalazine in distal ulcerative colitis: a multicenter, randomized, double-blind study.
Biancone L; Gionchetti P; Blanco Gdel V; Orlando A; Annese V; Papi C; Sostegni R; D'Incà R; Petruzziello C; Casa A; Sica G; Calabrese E; Campieri M; Pallone F
Dig Liver Dis; 2007 Apr; 39(4):329-37. PubMed ID: 17347061
[TBL] [Abstract][Full Text] [Related]
7. The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine.
Kruis W; Bar-Meir S; Feher J; Mickisch O; Mlitz H; Faszczyk M; Chowers Y; Lengyele G; Kovacs A; Lakatos L; Stolte M; Vieth M; Greinwald R
Clin Gastroenterol Hepatol; 2003 Jan; 1(1):36-43. PubMed ID: 15017515
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, active-controlled trial.
Miner PB; Wedel MK; Xia S; Baker BF
Aliment Pharmacol Ther; 2006 May; 23(10):1403-13. PubMed ID: 16669955
[TBL] [Abstract][Full Text] [Related]
9. Budesonide foam versus budesonide enema in active ulcerative proctitis and proctosigmoiditis.
Gross V; Bar-Meir S; Lavy A; Mickisch O; Tulassay Z; Pronai L; Kupcinskas L; Kiudelis G; Pokrotnieks J; Kovács A; Faszczyk M; Razbadauskas A; Margus B; Stolte M; Müller R; Greinwald R;
Aliment Pharmacol Ther; 2006 Jan; 23(2):303-12. PubMed ID: 16393311
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis.
Levine DS; Riff DS; Pruitt R; Wruble L; Koval G; Sales D; Bell JK; Johnson LK
Am J Gastroenterol; 2002 Jun; 97(6):1398-407. PubMed ID: 12094857
[TBL] [Abstract][Full Text] [Related]
11. MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations.
Lichtenstein GR; Kamm MA; Sandborn WJ; Lyne A; Joseph RE
Aliment Pharmacol Ther; 2008 Jun; 27(11):1094-102. PubMed ID: 18363894
[TBL] [Abstract][Full Text] [Related]
12. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis.
Dignass AU; Bokemeyer B; Adamek H; Mross M; Vinter-Jensen L; Börner N; Silvennoinen J; Tan G; Pool MO; Stijnen T; Dietel P; Klugmann T; Vermeire S; Bhatt A; Veerman H
Clin Gastroenterol Hepatol; 2009 Jul; 7(7):762-9. PubMed ID: 19375519
[TBL] [Abstract][Full Text] [Related]
13. Clinical trial: controlled, open, randomized multicentre study comparing the effects of treatment on quality of life, safety and efficacy of budesonide or mesalazine enemas in active left-sided ulcerative colitis.
Hartmann F; Stein J;
Aliment Pharmacol Ther; 2010 Aug; 32(3):368-76. PubMed ID: 20491741
[TBL] [Abstract][Full Text] [Related]
14. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial.
Hanauer SB; Sandborn WJ; Kornbluth A; Katz S; Safdi M; Woogen S; Regalli G; Yeh C; Smith-Hall N; Ajayi F
Am J Gastroenterol; 2005 Nov; 100(11):2478-85. PubMed ID: 16279903
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the efficacy and safety of Eudragit-L-coated mesalazine tablets with ethylcellulose-coated mesalazine tablets in patients with mild to moderately active ulcerative colitis.
Gibson PR; Fixa B; Pekárková B; Bátovský M; Radford-Smith G; Tibitanzl J; Gabalec L; Florin TH; Greinwald R
Aliment Pharmacol Ther; 2006 Apr; 23(7):1017-26. PubMed ID: 16573804
[TBL] [Abstract][Full Text] [Related]
16. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis.
Pruitt R; Hanson J; Safdi M; Wruble L; Hardi R; Johanson J; Koval G; Riff D; Winston B; Cross A; Doty P; Johnson LK
Am J Gastroenterol; 2002 Dec; 97(12):3078-86. PubMed ID: 12492193
[TBL] [Abstract][Full Text] [Related]
17. Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study.
D'Haens G; Hommes D; Engels L; Baert F; van der Waaij L; Connor P; Ramage J; Dewit O; Palmen M; Stephenson D; Joseph R
Aliment Pharmacol Ther; 2006 Oct; 24(7):1087-97. PubMed ID: 16984503
[TBL] [Abstract][Full Text] [Related]
18. A clinical trial on absorption and N-acetylation of oral and rectal mesalazine.
Dilger K; Trenk D; Rössle M; Cap M; Zähringer A; Wacheck V; Remmler C; Cascorbi I; Kreisel W; Novacek G
Eur J Clin Invest; 2007 Jul; 37(7):558-65. PubMed ID: 17576207
[TBL] [Abstract][Full Text] [Related]
19. Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol.
Prantera C; Kohn A; Campieri M; Caprilli R; Cottone M; Pallone F; Savarino V; Sturniolo GC; Vecchi M; Ardia A; Bellinvia S
Aliment Pharmacol Ther; 2009 Nov; 30(9):908-18. PubMed ID: 19678813
[TBL] [Abstract][Full Text] [Related]
20. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis.
Lichtenstein GR; Kamm MA; Boddu P; Gubergrits N; Lyne A; Butler T; Lees K; Joseph RE; Sandborn WJ
Clin Gastroenterol Hepatol; 2007 Jan; 5(1):95-102. PubMed ID: 17234558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]